Next-generation clinical trials: Novel strategies to address thechallenge of tumor molecular heterogeneity

Molecular Oncology

Volumn 9, Issue 5, 2015, Pages 967-996

  Catenacci, Daniel V T ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Esophagogastric cancer; Esophagus cancer; Expansion Platform Designs; Gastric cancer; Gastroesophageal cancer; Inter patient heterogeneity; Intra patient heterogeneity; Molecular heterogeneity; Next generation clinical trials; PANGEA

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIRUBICIN; LAPATINIB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RAMUCIRUMAB; RILOTUMUMAB; TRASTUZUMAB;

CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG TARGETING; ESOPHAGUS CANCER; GENETIC HETEROGENEITY; HUMAN; INTER PATIENT HETEROGENEITY; INTRA PATIENT HETEROGENEITY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TUMOR MOLECULAR HETEROGENEITY; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS;

EID: 84928582479     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.09.011     Document Type: Review

References (150)

1. Abrams J., Conley B., Mooney M., et al. National cancer institute's precision medicine initiatives for the new national clinical trials network. Am. Soc. Clin. Oncol. Educ. Book 2014, 71-76.
2. Alix-Panabieres C., Pantel K. Challenges in circulating tumour cell research. Nat. Rev. Cancer 2014, 14:623-631.
3. Arena V., Pennacchia I., Vecchio F.M., Carbone A. HER-2 intratumoral heterogeneity. Mod. Pathol. 2013, 26:607-609.
4. Baines A.T., Xu D., Der C.J. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 2011, 3:1787-1808.
5. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
6. Bang Y.J., Im S.A., Lee K.W., et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: a randomized, double-blind phase II study. J.Clin. Oncol. 2013, 31. Abstr 4013.
7. Barker A.D., Sigman C.C., Kelloff G.J., Hylton N.M., Berry D.A., Esserman L.J. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 2009, 86:97-100.
8. Bedard P.L., Hansen A.R., Ratain M.J., Siu L.L. Tumour heterogeneity in the clinic. Nature 2013, 501:355-364.
9. Bellou S., Pentheroudakis G., Murphy C., Fotsis T. Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett. 2013, 338:219-228.
10. Bianco R., Melisi D., Ciardiello F., Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur. J. Cancer 2006, 42:290-294.
11. Blumenschein G.R., Saintigny P., Liu S., et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin. Cancer Res. 2013, 19:6967-6975.
12. Catenacci D.V., Henderson L., Xiao S.Y., et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011, 1:573-579.
13. Catenacci D.V., Cervantes G., Yala S., et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol. Ther. 2011, 12.
14. Catenacci D.V., Kozloff M., Kindler H.L., Polite B. Personalized colon cancer care in 2010. Semin. Oncol. 2011, 38:284-308.
15. Catenacci D., Henderson L., Liao W., Burrows J., Hembrough T. KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined anti-MET/AKT therapy. Cancer Res. 2013, Abstr 141239.
16. Catenacci D., Polite B., Henderson L., et al. Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity - PANGEA. J.Clin. Oncol. 2014, GI ASCO 2014, Abstr 60.
17. Catenacci D.V., Liao W.L., Thyparambil S., et al. Absolute quantitation of met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One 2014, 9:e100586.
18. Catenacci D.V., Amico A.L., Nielsen S.M., et al. Tumor genome analysis includes germline genome: are we ready for surprises?. Int. J. Cancer 2014.
19. Cepero V., Sierra J.R., Corso S., et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 2010, 70:7580-7590.
20. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N.Engl. J. Med. 2011, 364:2507-2516.
21. Cohen D.J., Christos P.J., Kindler H.L., et al. Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal (GEJ) carcinoma: a New York Cancer Consortium led phase II randomized study. J.Clin. Oncol. 2013, 31. Abstr 4011.
22. Collins F.S., Hamburg M.A. First FDA authorization for next-generation sequencer. N.Engl. J. Med. 2013, 369:2369-2371.
23. 2014. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209.
24. Corso S., Giordano S. Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. Cancer Discov. 2013, 3:978-992.
25. Dancey J.E., Dobbin K.K., Groshen S., et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 2010, 16:1745-1755.
26. Dancey J.E., Bedard P.L., Onetto N., Hudson T.J. The genetic basis for cancer treatment decisions. Cell 2012, 148:409-420.
27. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
28. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N.Engl. J. Med. 2002, 347:472-480.
29. Deng N., Goh L.K., Wang H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61:673-684.
30. Deng Y., Wang C.C., Choy K.W., et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 2014, 538:217-227.
31. Devaud C., John L.B., Westwood J.A., Darcy P.K., Kershaw M.H. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013, 2:e25961.
32. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J.Clin. Oncol. 2014, 32:579-586.
33. Douillard J.Y., Rong A., Sidhu R. RAS mutations in colorectal cancer. N.Engl. J. Med. 2013, 369:2159-2160.
34. Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N.Engl. J. Med. 2013, 369:1023-1034.
35. Dowlati A., Haaga J., Remick S.C., et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin. Cancer Res. 2001, 7:2971-2976.
36. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N.Engl. J. Med. 2006, 355:2408-2417.
37. Dulak A.M., Schumacher S.E., van Lieshout J., et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012, 72:4383-4393.
38. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
39. ESMO Results from the CALGB/SWOG 80405 and FIRE-3 (AIO KRK-0306) studies in all RAS wild type population. 2014 2014, (accessed at:. http://www.esmo.org/Oncology-News/Results-From-the-CALGB-SWOG-80405-and-FIRE-3-AIO-KRK-0306-Studies-In-All-RAS-Wild-Type-Population.http://www.esmo.org/Oncology-News/Results-From-the-CALGB-SWOG-80405-and-FIRE-3-AIO-KRK-0306-Studies-In-All-RAS-Wild-Type-Population.
40. Faivre S., Djelloul S., Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol. 2006, 33:407-420.
41. Fauvel B., Yasri A. Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. MAbs 2014, 6:838-851.
42. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
43. Fedele C., Tothill R.W., McArthur G.A. Navigating the challenge of tumor heterogeneity in cancer therapy. Cancer Discov. 2014, 4:146-148.
44. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N.Engl. J. Med. 2010, 363:809-819.
45. Frampton G.M., Fichtenholtz A., Otto G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 2013, 31:1023-1031.
46. Freidlin B., Korn E.L. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat. Rev. Clin. Oncol. 2014, 11:81-90.
47. Freidlin B., McShane L.M., Korn E.L. Randomized clinical trials with biomarkers: design issues. J.Natl. Cancer Inst. 2010, 102:152-160.
48. Fuchs C.S., Tomasek J., Yong C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383:31-39.
49. Garraway L.A., Verweij J., Ballman K.V. Precision oncology: an overview. J.Clin. Oncol. 2013, 31:1803-1805.
50. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N.Engl. J. Med. 2012, 366:883-892.
51. Gimbrone M.A., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy invivo by prevention of neovascularization. J.Exp. Med. 1972, 136:261-276.
52. Gomez-Martin C., Plaza J.C., Pazo-Cid R., et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J.Clin. Oncol. 2013, 31:4445-4452.
53. Griffin J. The biology of signal transduction inhibition: basic science to novel therapies. Semin. Oncol. 2001, 28:3-8.
54. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J.Clin. Oncol. 2008, 26:5326-5334.
55. Harris A.L., Fox S., Bicknell R., et al. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer 1994, 74:1021-1025.
56. Hecht J.R., Bang Y.J., Qin S., et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophgael, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial. J.Clin. Oncol. 2013, 31. abstr LBA4001.
57. Hembrough T., Liao W., Henderson L., Xu P., Burrows J., Catenacci D. Development of a quantitative gastroesophageal cancer selected reaction monitoring mass spectrometric multi-plex assay for use in FFPE tumor tissues. 24th EORTC-NCI-AACR Symposium Dublin, Ireland November 6-9, 2012 2012, (Abstr 561).
58. Hirsch F.R., Bunn P.A., Herbst R.S. "Companion diagnostics": has their time come and gone?. Clin. Cancer Res. 2014, 20:4422-4424.
59. Holbrook J.D., Parker J.S., Gallagher K.T., et al. Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J.Transl. Med. 2011, 9:119.
60. Hull D.L. Deconstructing Darwin: evolutionary theory in context. J.Hist. Biol. 2005, 38:137-152.
61. Islam M.F., Hoque M.M., Banik R.S., et al. Comparative analysis of differential network modularity in tissue specific normal and cancer protein interaction networks. J.Clin. Bioinforma 2013, 3:19.
62. Iveson T., Donehower R.C., Davidenko I., et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014.
63. Joensuu H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol. 2008, 9:304.
64. June C.H., Maus M.V., Plesa G., et al. Engineered T cells for cancer therapy. Cancer Immunol. Immunother. 2014, 63:969-975.
65. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5:689-698.
66. Kakarla S., Song X.T., Gottschalk S. Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy 2012, 4:1129-1138.
67. Kaplan R., Maughan T., Crook A., et al. Evaluating many treatments and biomarkers in oncology: a new design. J.Clin. Oncol. 2013, 31:4562-4568.
68. Karaman M.W., Herrgard S., Treiber D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
69. Keenan B.P., Jaffee E.M., Armstrong T.D. Tumor immunology: multidisciplinary science driving basic and clinical advances. Cancer Immunol. Res. 2013, 1:16-23.
70. Khoo B.L., Warkiani M.E., Tan D.S., et al. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. PLoS One 2014, 9:e99409.
71. Khoury J.D., Catenacci D.V. Next-generation companion diagnostics: promises, challenges, and solutions. Arch. Pathol. Lab Med. 2014.
72. Kim E.S., Herbst R.S., Wistuba, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011, 1:44-53.
73. Kurzrock R., Kantarjian H., Stewart D.J. A cancer trial scandal and its regulatory backlash. Nat. Biotechnol. 2014, 32:27-31.
74. Lai T.L., Lavori P.W., Shih M.C., Sikic B.I. Clinical trial designs for testing biomarker-based personalized therapies. Clin. Trials 2012, 9:141-154.
75. Le D.T., Jaffee E.M. Harnessing immune responses in the tumor microenvironment: all signals needed. Clin. Cancer Res. 2013, 19:6061-6063.
76. Leary A., Johnston S.R. Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest. 2007, 25:347-365.
77. Leary R.J., Sausen M., Kinde I., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 2012, 4. 162ra54.
78. Lee H.E., Park K.U., Yoo S.B., et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur. J. Cancer 2013, 49:1448-1457.
79. Lee J.M., Hays J.L., Noonan A.M., et al. Feasibility and safety of sequential research-related tumor core biopsies in clinical trials. Cancer 2013, 119:1357-1364.
80. Lengauer C., Diaz L.A., Saha S. Cancer drug discovery through collaboration. Nat. Rev. Drug Discov. 2005, 4:375-380.
81. Longo D.L. Tumor heterogeneity and personalized medicine. N.Engl. J. Med. 2012, 366:956-957.
82. Lordick F., Kang Y.K., Chung H.C., et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013, 14:490-499.
83. Lordick F., Kang Y., Salman P., et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer from the EXPAND study. J.Clin. Oncol. 2013, 31. Suppl. ; abstr 2012.
84. Mandrekar S.J., Sargent D.J. Design of clinical trials for biomarker research in oncology. Clin. Investig. (Lond) 2011, 1:1629-1636.
85. Mauro M.J., O'Dwyer M., Heinrich M.C., Druker B.J. STI571: a paradigm of new agents for cancer therapeutics. J.Clin. Oncol. 2002, 20:325-334.
86. Maus M.V., Fraietta J.A., Levine B.L., Kalos M., Zhao Y., June C.H. Adoptive immunotherapy for cancer or viruses. Annu. Rev. Immunol. 2014, 32:189-225.
87. Melero I., Gaudernack G., Gerritsen W., et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 2014, 11:509-524.
88. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
89. Mendelsohn J. Personalizing oncology: perspectives and prospects. J.Clin. Oncol. 2013, 31:1904-1911.
90. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
91. Muro K., Bang Y.J., Shankaran V., et al. A phase 1b study of Pembrolizumab (Pembro; MK-3475) in patients with advanced gastric Cancer. ESMO 2014, Oral Abstr LBA15 2014.
92. Navin N.E., Hicks J. Tracing the tumor lineage. Mol. Oncol. 2010, 4:267-283.
93. Navin N., Krasnitz A., Rodgers L., et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010, 20:68-80.
94. 2014. Neratinib graduates to I-SPY 3. Cancer Discov. 4, 624.
95. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
96. Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J.Clin. Oncol. 2011, 29:3968-3976.
97. Ohtsu A., Ajani J.A., Bai Y.X., et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J.Clin. Oncol. 2013, 31:3935-3943.
98. Olopade O.I. Obituary: Janet Davison Rowley 1925-2013. Cell 2014, 156:390-391.
99. Overman M.J., Modak J., Kopetz S., et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J.Clin. Oncol. 2013, 31:17-22.
100. Pantel K., Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction?. Cancer Res. 2013, 73:6384-6388.
101. Parkinson D.R., Johnson B.E., Sledge G.W. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin. Cancer Res. 2012, 18:619-624.
102. Parmigiani G., Boca S., Lin J., Kinzler K.W., Velculescu V., Vogelstein B. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 2009, 93:17-21.
103. Pegram M., Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin. Oncol. 2000, 27:13-19.
104. Petty R.D., Dahle-Smith A., Miedzybrodzka Z., et al. Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): results of biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG). J.Clin. Oncol. 2014, 32. 5s, Abstr 4016.
105. Poplin E., Wasan H., Rolfe L., et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J.Clin. Oncol. 2013, 31:4453-4461.
106. 2014. Positive results for drug combo in I-SPY 2 trial. Cancer Discov. 4 (OF2).
107. Rowley J.D. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann. Genet. 1973, 16:109-112.
108. Rowley J.D., Wolman S.R., Horland A.A. Letter: another variant translocation in chronic myelogenous leukemia-revisited. New Engl. J. Med. 1976, 295:900-901.
109. Sargent D.J., Conley B.A., Allegra C., Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J.Clin. Oncol. 2005, 23:2020-2027.
110. Satoh T., Xu R.H., Chung H.C., et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study. J.Clin. Oncol. 2014, 32:2039-2049.
111. Schwarzenbach H., Nishida N., Calin G.A., Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 2014, 11:145-156.
112. Sehdev A., Catenacci D.V. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J.Hematol. Oncol. 2013, 6:66.
113. Sehdev A., Catenacci D.V. Gastroesophageal cancer: focus on epidemiology, classification, and staging. Discov. Med. 2013, 16:103-111.
114. Seol H., Lee H.J., Choi Y., et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod. Pathol. 2012, 25:938-948.
115. Shimada H. Is "liquid biopsy" useful for assessing HER2 status in gastric cancer?. J.Gastroenterol. 2014.
116. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 2012, 320:130-137.
117. Simon R., Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res. 2004, 10:6759-6763.
118. Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J.Natl. Cancer Inst. 2009, 101:1446-1452.
119. Slamon D.J., deKernion J.B., Verma I.M., Cline M.J. Expression of cellular oncogenes in human malignancies. Science 1984, 224:256-262.
120. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
121. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N.Engl. J. Med. 2001, 344:783-792.
122. Smolen G.A., Sordella R., Muir B., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U S A 2006, 103:2316-2321.
123. Speicher M.R., Pantel K. Tumor signatures in the blood. Nat. Biotechnol. 2014, 32:441-443.
124. Stricker T., Catenacci D.V., Seiwert T.Y. Molecular profiling of cancer-the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin. Oncol. 2011, 38:173-185.
125. Sullivan R.J., Lorusso P.M., Flaherty K.T. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin. Cancer Res. 2013, 19:5283-5291.
126. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012, 72:4875-4882.
127. Tsao A.S., Liu S., Lee J.J., et al. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J.Thorac. Oncol. 2013, 8:658-661.
128. Turke A.B., Zejnullahu K., Wu Y.L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
129. Vakiani E., Janakiraman M., Shen R., et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J.Clin. Oncol. 2012, 30:2956-2962.
130. Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N.Engl. J. Med. 2012, 367:1783-1791.
131. Videira M., Arranja A., Rafael D., Gaspar R. Preclinical development of siRNA therapeutics: towards the match between fundamental science and engineered systems. Nanomedicine 2014, 10:689-702.
132. Vignot S., Frampton G.M., Soria J.C., et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J.Clin. Oncol. 2013, 31:2167-2172.
133. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
134. von Minckwitz G., du Bois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J.Clin. Oncol. 2009, 27:1999-2006.
135. Waddell T., Chau I., Cunningham D., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013, 14:481-489.
136. Wang K., Kan J., Yuen S.T., et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 2011, 43:1219-1223.
137. Wang S.J., Hung H.M., O'Neill R. Paradigms for adaptive statistical information designs: practical experiences and strategies. Stat. Med. 2012, 31:3011-3023.
138. Warth A., Muley T., Herpel E., et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 2012, 61:1017-1025.
139. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
140. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res. 2008, 68:3077-3080. discussion 80.
141. Wilke H., Muro K., Van Cutsem E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014.
142. Wilson T.R., Fridlyand J., Yan Y., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
143. Yan R., Hallam A., Stockley P.G., Boyes J. Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy. Biochem. J. 2014, 461:1-13.
144. Yap T.A., Gerlinger M., Futreal P.A., Pusztai L., Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 2012, 4. 127ps10.
145. Yap T.A., Omlin A., de Bono J.S. Development of therapeutic combinations targeting major cancer signaling pathways. J.Clin. Oncol. 2013, 31:1592-1605.
146. Yoon H.H., Shi Q., Sukov W.R., et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. Journal of clinical oncology. official J. Am. Soc. Clin. Oncol. 2012, 30:3932-3938.
147. Zang Z.J., Cutcutache I., Poon S.L., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 2012, 44:570-574.
148. Zhang L., Yang J., Cai J., et al. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci. Rep. 2013, 3:2992.
149. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12:735-742.
150. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6:715-727.